Lamotrigine analysis in blood and brain by high-performance liquid chromatography.
A reversed-phase high-performance liquid chromatography assay was developed and validated to determine plasma and brain lamotrigine concentrations allowing pharmacokinetic-pharmacodynamic studies of this new antiepileptic drug in patients and laboratory animals. Lamotrigine and its internal standard were extracted, under alkaline conditions, from plasma and brain homogenate, into ethyl acetate; brain proteins were previously precipitated with trichloroacetic acid. The method was linear between 0.1 and 15.0 mg/l for plasma, with a detection limit of 0.008 mg/l, and between 0.1 and 5.0 mg/l for brain homogenate, with a detection limit of 0.023 mg/l. The method proved to be simple, useful and appropriate, not only for clinical and experimental research, but also for routine monitoring of lamotrigine concentrations in patients.
Castel-Branco
M M
MM
Laboratory of Pharmacology, Faculty of Pharmacy, Coimbra University, Portugal.
Almeida
A M
AM
Falcão
A C
AC
Macedo
T A
TA
Caramona
M M
MM
Lopez
F G
FG
D000818:Animals; D000927:Anticonvulsants / Q000032:analysis* / Q000097:blood; D001923:Brain Chemistry; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004355:Drug Stability; D004827:Epilepsy / Q000097:blood; D006801:Humans; D000077213:Lamotrigine; D015394:Molecular Structure; D051381:Rats; D012680:Sensitivity and Specificity; D014227:Triazines / Q000032:analysis* / Q000097:blood / Q000592:standards
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine